Get the Stockscreener App
280.07
0.02%
0.06
After Hours:
280.25
0.18
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $280.07, with a volume of 6.60M.
It is up +0.02% in the last 24 hours and down -11.64% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$280.01
Open:
$279
24h Volume:
6.60M
Relative Volume:
2.78
Market Cap:
$150.26B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
19.91
EPS:
14.07
Net Cash Flow:
$6.28B
1W Performance:
-2.71%
1M Performance:
-11.64%
6M Performance:
-8.43%
1Y Performance:
+5.98%
1-Day Range:
$278.00
$282.69
1-Week Range:
$257.80
$297.32
52-Week Range:
$257.80
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
280.07 | 150.26B | 32.53B | 4.23B | 6.28B | 14.07 |
|
LLY
Lilly Eli Co
|
788.19 | 752.65B | 40.86B | 8.37B | -2.28B | 5.4193 |
|
NVO
Novo Nordisk Adr
|
106.13 | 471.56B | 39.36B | 13.79B | 9.83B | 2.4077 |
|
JNJ
Johnson Johnson
|
155.40 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
|
ABBV
Abbvie Inc
|
183.08 | 323.72B | 55.53B | 5.12B | 15.62B | 3.65 |
|
MRK
Merck Co Inc
|
103.12 | 260.72B | 63.17B | 12.15B | 14.84B | 1.80 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Drug Delivers More Weight Loss Than Competitors - Newsweek
New Apprentice Program Draws Talent from Unexpected Sources - Amgen
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You (NASDAQ:AMGN) - Seeking Alpha
Amgen stock holds Buy rating, TD Cowen highlights MariTide's competitive edge in obesity treatment - Investing.com
BNP Paribas Reduces Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’ - MSN
Healthcare of Ontario Pension Plan Trust Fund Buys 303,016 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide achieves up to 20% weight loss in Phase 2 trial - World Pharmaceutical Frontiers
Glenmede Trust Co. NA Sells 42,532 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study - Yahoo Finance
Fmr LLC Buys 181,703 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The Manufacturers Life Insurance Company Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen's Weight Loss Result Is a Win for Eli Lilly - sharewise
Fisher Asset Management LLC Acquires 17,974 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen: Checks All The Wrong Boxes (NASDAQ:AMGN) - Seeking Alpha
AMGN Stock: MariTide Faces Dropout Challenges - Value the Markets
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For - Citeline
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - MedCity News
Given dosing advantage, Amgen drug may not need best-in-class weight loss - BioCentury
Amgen raises awareness of thyroid eye disease - KOIN.com
Amgen: MariTide Underwhelms, But There Are Ways To Win (NASDAQ:AMGN) - Seeking Alpha
S&P 500 rises slightly following Trump tariff plans; Amgen weighs on Dow: Live updates - CNBC
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows - The New York Times
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations - Investopedia
Amgen shares fall on anti-obesity drug; rivals Novo and Lilly gain - Yahoo Finance
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know. - Barron's
Amgen share price plummets despite Phase II weight loss success - Clinical Trials Arena
Amgen decline on MariTide data could be due to lack of more details - MSN
Amgen decline on MariTide data could be due to lack of more details (AMGN:NASDAQ) - Seeking Alpha
Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More - MSN
Amgen stock slips as obesity drug study disappoints Wall Street - Yahoo Finance
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark - BioPharma Dive
Amgen Falls as Weight-Loss Shot Results Disappoint Street - Yahoo Finance
Amgen Drug Cut Weight in Closely Watched Study - MSN
Amgen Inc (AMGN) Trading Down 11.91% on Nov 26 - GuruFocus.com
Amgen tumbles to year's low despite weightloss trial success - Proactive Investors USA
Amgen’s MariTide falls short of analyst expectations in obesity - The Pharma Letter
Amgen’s Obesity Drug Making Waves - Baystreet.ca
Amgen Obesity Drug Cut Weight in Closely Watched Study - The Wall Street Journal
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares - Reuters.com
Principal Street Partners LLC Has $6.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound - Yahoo! Voices
Amgen stock touches 52-week low at $260.55 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $260.55 amid market shifts - Investing.com Australia
Amgen, Boeing share losses lead Dow's 200-point fall - MarketWatch
Amgen plunges 11%, hits lowest level in a year - baha news
Stocks Open Mixed. Amgen Is Dragging on the Dow. - Yahoo! Voices
Amgen shows 20% weight loss in once-monthly injectable MariTide - Yahoo Finance
D.A. Davidson & CO. Has $70.16 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test - Yahoo! Voices
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):